Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

Ruochen Jia, Thomas Balligand, Vasyl Atamanyuk, Harini Nivarthi, Erica Xu, Leon Kutzner, Jakob Weinzierl, Audrey Nedelec, Stefan Kubicek, Roman Lesyk, Oleh Zagrijtschuk, Stefan N. Constantinescu, Robert Kralovics

Blood (2021) 137 (14): 1920–1931.

https://doi.org/10.1182/blood.2020006264

Published: 2021

Includes: Supplemental data

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Jessica L. Bridgford, Su Min Lee, Christine M. M. Lee, Paola Guglielmelli, Elisa Rumi, Daniela Pietra, Stephen Wilcox, Yash Chhabra, Alan F. Rubin, Mario Cazzola, Alessandro M. Vannucchi, Andrew J. Brooks, Matthew E. Call, Melissa J. Call

Blood (2020) 135 (4): 287–292.

https://doi.org/10.1182/blood.2019002561

Published: 2020

Includes: Supplemental data

Journal Articles

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Nathan Eaton, BS, Melissa M. Lee-Sundlov, PhD, Theresa A. Dlugi, PhD, Jon Wieser, BS, Haley E. Ramsey, PhDMSc, Martha Sola-Visner, MD, Karin M. Hoffmeister, MD, Hervé Falet, PhD

Blood (2019) 134 (Supplement_1): 2477.

https://doi.org/10.1182/blood-2019-126820

Published: 2019

Journal Articles

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Stephan Wilmes, PhD, Maximillian Hafer, BSc, Tess A Stanly, Ignacio Moraga, PhD, Joni Vuorio, PhD, Chetan Poojari, PhD, Vivek Sharma, PhD, Sara Löchte, PhD, Katiuska Pulgar Prieto, BSc, Julie A Tucker, PhD, Stevan R Hubbard, PhD, K.Christopher Garcia, PhD, Ilpo Vattulainen, PhD, Ian Hitchcock, PhD, Jacob Piehler, PhD

Blood (2019) 134 (Supplement_1): 2962.

https://doi.org/10.1182/blood-2019-129234

Published: 2019

Journal Articles

The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia

Tatiana V Makarik, PhD, Adhamjon O Abdullaev, MD PhD, Sergei M. Kulikov, PhD, Elena E Nikulina, Svetlana A Treglazova, Irina N Subortseva, MD, Alla M. Kovrigina, MD PhD, Anait L. Melikyan, MD PhD, Andrey B Sudarikov, PhD DSc, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5400.

https://doi.org/10.1182/blood-2019-124767

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Mutated CALR : tails from the crypt

Jerry L. Spivak

Blood (2019) 133 (25): 2630–2631.

https://doi.org/10.1182/blood-2019-04-901132

Published: 2019

Journal Articles

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Blood (2019) 133 (25): 2669–2681.

https://doi.org/10.1182/blood-2018-09-874578

Published: 2019

Includes: Supplemental data

Journal Articles

Platelet Apoptosis and PAI-1 Content Are Involved in the Procoagulant Profile of Immune Thrombocytopenia Patients Responders to Agonists of Thrombopoietin Receptor.

Raul Justo Sanz, Elena Monzón Manzano, Ihosvany Fernandez-Bello, Teresa Álvarez-Roman, Mónica Martín, María Isabel Rivas Pollmar, Miguel A. Canales, Victor Jimenez-Yuste, Nora Butta, PhD

Blood (2018) 132 (Supplement 1): 3738.

https://doi.org/10.1182/blood-2018-99-115898

Published: 2018

Journal Articles

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Blood (2018) 132 (Supplement 1): 4.

https://doi.org/10.1182/blood-2018-99-118348

Published: 2018

Journal Articles

In Frame Calr Exon 9 Mutations: Often Ignored but Potentially Significant

Richard Wong, MD, Shulei Sun, Huan-You Wang, MD PhD, Helen E. Broome, MD, Sarah Murray, PhD, John Thorson, MD PhD

Blood (2018) 132 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2018-99-119897

Published: 2018

Journal Articles

Characterization of Hematopoietic Differentiation Profiles of MPN Patient-Derived Inducible Pluripotent Stem Cells Harboring Homozygous Vs Heterozygous Calreticulin Mutations

Lijuan Han, MD, Marcelo A. Szymanski Toledo, PhD, Alexandre Theocharides, MD, Angela Maurer, M.Sc, Tim H. Brümmendorf, MD, Martin Zenke, PhD, Nicolas Chatain, PhD, Steffen Koschmieder, MD

Blood (2018) 132 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2018-99-113372

Published: 2018

Journal Articles

Wang X, Haylock D, Hu CS, et al. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood. 2016;127(26):3398-3409.

Blood (2017) 130 (25): 2809.

https://doi.org/10.1182/blood-2017-11-815340

Published: 2017

Journal Articles

Overexpression of Calreticulin Impairs Self-Renewal Capacity of Hematopoietic Stem Cells

Stefan Brooks, Sarah Morse, MS, Brianna Craver, MS, Hew Yeng Lai, Thanh Kim Nguyen, PhD, Daniel Kim, Angela G. Fleischman, MD PhD, Prasanthi Tata, Nilamani Jena, PhD, Zhong-Ying Liu, Richard A. Van Etten, MD PhD

Blood (2017) 130 (Supplement 1): 4937.

https://doi.org/10.1182/blood.V130.Suppl_1.4937.4937

Published: 2017

Journal Articles

Functional and Molecular Basis of Thrombopoietin Receptor Activation By Mutant Calreticulin

Shannon Elf, PhD, Nouran Abdelfattah, MPhil, April Joy Baral, MSc, BSc, Danielle Beeson, Amy Ko, Natalie Florescu, Edwin Chen, PhD, Ann Mullally, MD

Blood (2017) 130 (Supplement 1): 382.

https://doi.org/10.1182/blood.V130.Suppl_1.382.382

Published: 2017

Journal Articles

Localization of Mutant Calreticulin in the Golgi Apparatus Is Required for Its Oncogenic Capacity

Nami Masubuchi, Marito Araki, PhD, Erina Hayashi, BS, Yinjie Yang, PhD, Misa Imai, PhD, Yoshihiko Kihara, PhD, Yoshihisa Mizukami, PhD, Yumi Hironaka, BS, Hiraku Takei, MS, Yoko Edahiro, PhD, Akimichi Ohsaka, MD PhD, Norio Komatsu, MD

Blood (2017) 130 (Supplement 1): 1656.

https://doi.org/10.1182/blood.V130.Suppl_1.1656.1656

Published: 2017

Journal Articles

Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia

Ishac Nazy, PhD, Jane C. Moore, BSc, MT, Rumi Clare, B.Sc., James W. Smith, BSc MT, Nikola Ivetic, BSc, Vanessa D'Souza, B.Sc., John G. Kelton, MD FRCPC, Donald M. Arnold, MD

Blood (2016) 128 (22): 2548.

https://doi.org/10.1182/blood.V128.22.2548.2548

Published: 2016

Journal Articles

Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells

Mira EL Khoury, Gaelle Vertenoeil, Caroline Marty, Christophe Marzac, Matthieu Mosca, Christian Pecquet, PhD, Fabrizia Favale, Robert Kralovics, Najet Debili, Nicole Casadevall, MD, Hana Raslova, PhD, Stefan N. Constantinescu, MD PhD, Isabelle Plo, William Vainchenker, MD PhD

Blood (2016) 128 (22): 1959.

https://doi.org/10.1182/blood.V128.22.1959.1959

Published: 2016

Journal Articles

The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients

Xiaoli Wang, Cing Siang Hu, Jiajing Qiu, Ronald Hoffman, MD

Blood (2016) 128 (22): 950.

https://doi.org/10.1182/blood.V128.22.950.950

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Mutated CALR : tails from the crypt

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Platelet Apoptosis and PAI-1 Content Are Involved in the Procoagulant Profile of Immune Thrombocytopenia Patients Responders to Agonists of Thrombopoietin Receptor.

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

In Frame Calr Exon 9 Mutations: Often Ignored but Potentially Significant

Characterization of Hematopoietic Differentiation Profiles of MPN Patient-Derived Inducible Pluripotent Stem Cells Harboring Homozygous Vs Heterozygous Calreticulin Mutations

Wang X, Haylock D, Hu CS, et al. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood. 2016;127(26):3398-3409.

Overexpression of Calreticulin Impairs Self-Renewal Capacity of Hematopoietic Stem Cells

Functional and Molecular Basis of Thrombopoietin Receptor Activation By Mutant Calreticulin

Localization of Mutant Calreticulin in the Golgi Apparatus Is Required for Its Oncogenic Capacity

Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia

Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells

The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients

Email alerts

ASH Publications

American Society of Hematology